Table 1.

Selected Baseline Characteristics by Treatment Status at Enrollment, REACH-OUT (2010–2013)

Variable	PP-All N = 482	PP-C N = 308	PP-N N = 174	OAT N = 281	P Value, PP-All vs OAT	P Value, PP-N vs OAT
Age (Mean ± SD)	41.12 ± 12.6	42.0 ± 12.7	39.6 ± 12.2	42.1 ± 13.4	0.440	0.069
Male	344 (71%)	219 (72%)	125 (74%)	181 (66%)	0.046	0.074
Race					0.727	0.081
White	239 (50%)	170 (57%)	69 (42%)	133 (49%)
Black/African American	153 (32%)	80 (27%)	73 (44%)	90 (33%)
Multiracial/other	73 (15%)	49 (16%)	24 (14%)	48 (18%)
Ethnicity: Hispanic	65 (13%)	43 (14%)	22 (14%)	72 (26%)	<0.001	0.002
Married/committed	40 (8%)	29 (10%)	11 (7%)	35 (13%)	0.077	0.053
Medicare	238 (49%)	164 (55%)	74 (45%)	100 (38%)	<0.001	0.130
Medicaid	352 (73%)	236 (79%)	116 (70%)	169 (63%)	<0.001	0.119
Private residence	326 (68%)	213 (70%)	113 (67%)	212 (78%)	0.002	0.015
Lung condition	48 (10%)	28 (9%)	20 (12%)	15 (5%)	0.029	0.018
Smoking	346 (72%)	226 (74%)	120 (70%)	179 (64%)	0.015	0.183
Alcohol abuse	106 (22%)	73 (24%)	33 (19%)	47 (17%)	0.075	0.526
Substance abuse	114 (24%)	80 (26%)	34 (20%)	75 (27%)	0.386	0.113
Duration of schizophrenia in years (mean ± SD)	15.7 ± 12.9	16.5 ± 13.0	14.4 ± 12.5	13.9 ± 13.5	0.014	0.340
Paranoid schizophrenia	323 (67%)	203 (66%)	120 (69%)	178 (63%)	0.306	0.226
Schizophrenia severity					<0.001	<0.001
Chronic	169 (35%)	108 (36%)	61 (36%)	72 (26%)
Subchronic	118 (24%)	68 (23%)	50 (30%)	61 (22%)
Other/unspecified	180 (38%)	123 (41%)	57 (34%)	148 (53%)

Notes: (1) Percentage missing: age, 2%; gender, 2%; race, 4%; Hispanic ethnicity, 3%; marital status, 2%; Medicare, 4%; Medicaid, 4%; living situation, 2%; lung condition,<1%; smoking, <1%; alcohol, 1%; substance abuse, <1%; schizophrenia duration, 4%; schizophrenia severity, 2%

(2) Percentages reported are among the nonmissing

Abbreviations: OAT oral antipsychotic therapy, PP paliperidone palmitate, PP-C continuous user of paliperidone palmitate, PP-N new user of paliperidone palmitate, OAT oral antipsychotic therapy, SD standard deviation